Concerns about important biases, such as selection bias, serious confounding by indication, detection bias, or reverse causality, limit the interpretation of some previous observational studies quantifying dementia risk associated with GLP1 receptor agonists (Supplementary Table 14 for further details)
Lilly also committed an additional US$4.5 billion across Indiana manufacturing sites, with the company stating that planned production includes Foundayo, Zepbound, Mounjaro and retatrutide-related capacity, highlighting how manufacturing scale has become central to GLP-1 market leadership
Regular Physical Activity: Gentle exercise like walking can help stimulate bowel function
The reconstitution arithmetic itself is two steps
Smartshot is a long-acting B12 injection